阿片类药物使用障碍与全关节置换术后感染风险增加相关:一项大型数据库研究
基于2005至2014年Medicare数据库,匹配分析54,332例初次及翻修全髋/全膝关节置换患者,发现阿片类药物使用障碍患者术后90天手术部位感染和2年假体周围感染风险均显著升高,翻修术后的假体周围感染风险尤其突出。
要点
- 阿片类药物使用障碍患者初次全髋置换术后90天手术部位感染风险OR 1.85,2年假体周围感染风险OR 1.66。
- 翻修全髋置换术后2年假体周围感染风险OR 4.24,翻修全膝置换术后2年假体周围感染风险OR 4.94。
- 作者建议医疗系统和管理者认识相关感染风险并制定临床政策,鼓励外科医生采取多学科方法帮助患者术前减少阿片类药物消耗。
核心结论
- 在控制年龄、性别和合并症负担后,阿片类药物使用障碍患者接受全关节置换术后发生手术部位感染和假体周围感染的风险增加。
- 作者认为医疗系统和管理者应认识到阿片类药物使用障碍患者相关的假体周围感染和手术部位感染风险增加,并制定反映这些相关风险的临床政策。
- 作者建议这些发现应鼓励外科医生采取多学科方法帮助患者在关节置换术前减少阿片类药物消耗。
研究设计与样本
- 从PearlDiver超级计算机的Medicare分析文件中,采用ICD-9编码识别2005年至2014年间所有初次和翻修全关节置换术。
- 该数据库为全国性大型数据库之一,基于所有保险索赔全面纵向追踪患者而非特定医院就诊,错误率估计为1.3%。
- 使用布尔命令运算符形成术前有阿片类药物使用障碍病史的研究组,ICD-9诊断编码304.00至304.02和305.50至305.52用于识别阿片类药物使用障碍患者。
- 研究组患者按年龄、性别和合并症负担(Elixhauser合并症指数[ECI])与无阿片类药物使用障碍的对照者1:1匹配,ECI包含31种不同合并症。
- 查询产生研究人群54,332例:初次全髋置换14,944例(阿片类药物使用障碍n=7472),初次全膝置换23,680例(阿片类药物使用障碍n=11,840),翻修全髋置换8116例(阿片类药物使用障碍n=4058),翻修全膝置换7592例(阿片类药物使用障碍n=3796)。
主要发现
- 初次全髋置换患者中,阿片类药物使用障碍组90天手术部位感染风险OR 1.85(95%CI 1.51至2.25;p<0.001),2年假体周围感染风险OR 1.66(95%CI 1.42至1.93;p<0.001)。
- 初次全膝置换患者中,阿片类药物使用障碍组90天手术部位感染风险OR 1.72(95%CI 1.46至2.02;p<0.001),2年假体周围感染风险OR 1.31(95%CI 1.16至1.47;p<0.001)。
- 翻修全髋置换患者中,阿片类药物使用障碍组90天手术部位感染风险OR 1.89(95%CI 1.53至2.32;p<0.001),2年假体周围感染风险OR 4.24(95%CI 3.67至4.89;p<0.001)。
- 翻修全膝置换患者中,阿片类药物使用障碍组90天手术部位感染风险OR 1.88(95%CI 1.53至2.29;p<0.001),2年假体周围感染风险OR 4.94(95%CI 4.24至5.76;p<0.001)。
关键数值与推荐
- 主要结局为术后90天手术部位感染和术后2年假体周围感染,通过ICD-9编码识别。
- 采用逻辑回归分析计算阿片类药物使用障碍患者相比匹配对照者发生感染的风险。
- 证据等级为III级,治疗性研究。
临床怎么用
- 作者认为医疗系统和管理者应认识到阿片类药物使用障碍患者相关的假体周围感染和手术部位感染风险增加,并制定反映这些相关风险的临床政策。
- 作者建议这些发现应鼓励外科医生采取多学科方法帮助患者在关节置换术前减少阿片类药物消耗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent studies have shown that patients with opioid use disorder have impaired immunity. However, few studies with large patient populations have evaluated the risks of surgical site infection (SSI) and prosthetic joint infection (PJI) with opioid use disorder after total joint arthroplasty (TJA), and there is a lack of evidence for revision TJA in particular. QUESTIONS/PURPOSES: Are patients with opioid use disorder who undergo (1) primary THA, (2) primary TKA, (3) revision THA, or (4) revision TKA at a higher risk of experiencing SSIs 90 days after surgery or PJIs 2 years after surgery than those who do not have opioid use disorder? METHODS: All primary and revision TJAs performed between 2005 and 2014 were identified from the Medicare Analytical Files of the PearlDiver Supercomputer using ICD-9 codes. This database is one of the largest nationwide databases; it comprehensively and longitudinally tracks patients based on all insurance claims rather than particular hospital visits, and has a low error rate (estimated at 1.3%). Boolean command operators were used to form a study group of patients with a history of opioid use disorder before surgery. ICD-9 diagnosis codes 304.00 to 304.02 and 305.50 to 305.52 were used to identify patients with opioid use disorder. Study group patients were matched 1:1 to control participants without opioid use disorder undergoing TJA, according to age, sex, and comorbidity burden (Elixhauser comorbidity index [ECI]). The ECI is comprised of 31 different comorbidities and can be used for large administrative databases. The query yielded a study population of 54,332 patients: 14,944 undergoing primary THA (opioid use disorder: n = 7472), 23,680 undergoing primary TKA (opioid use disorder: n = 11,840), 8116 undergoing revision THA (opioid use disorder: n = 4058), and 7592 undergoing revision TKA (opioid use disorder: n = 3796). The primary outcomes analyzed were SSI at 90 days and PJI at 2 years postoperatively, which were identified with ICD-9 codes. Logistic regression analyses were performed to calculate the risk that an infection would develop in a patient with opioid use disorder compared with the matched control patients without opioid use disorder. RESULTS: Patients with opioid use disorder undergoing primary THA had an increased risk of SSI at 90 days (OR 1.85 [95% CI 1.51 to 2.25]; p < 0.001) and PJI at 2 years (OR 1.66 [95% CI 1.42 to 1.93]; p < 0.001). Compared with matched controls, opioid use disorder patients undergoing primary TKA had an increased risk of SSI at 90 days (OR 1.72 [95% CI 1.46 to 2.02]; p < 0.001) and PJI at 2 years (OR 1.31 [95% CI 1.16 to 1.47]; p < 0.001). Similarly, for revision THAs, there was an increase in 90-day SSIs (OR 1.89 [95% CI 1.53 to 2.32]; p < 0.001) and 2-year PJIs (OR 4.24 [95% CI 3.67 to 4.89]; p < 0.001). The same held for revision TKAs for 90-day SSIs (OR 1.88 [95% CI 1.53 to 2.29]; p < 0.001) and 2-year PJIs (OR 4.94 [95% CI 4.24 to 5.76]; p < 0.001). CONCLUSIONS: After accounting for age, sex, and comorbidity burden, these results revealed that patients with opioid use disorder undergoing TJA were at increased risk of having SSIs and PJIs. Based on these findings, healthcare systems and/or administrators should recognize the increased associated PJI and SSI risks in patients with opioid use disorder and enact clinical policies that reflect these associated risks. Additionally, these findings should encourage surgeons to pursue multidisciplinary approaches to help patients reduce their opioid consumption before their arthroplasty procedure. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Sodhi N, Anis HK, Acuña AJ, et al. Opioid Use Disorder Is Associated with an Increased Risk of Infection after Total Joint Arthroplasty: A Large Database Study. Clin Orthop Relat Res. 2020. PMID: 32662956. doi:10.1097/CORR.0000000000001390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。